Pappas Ventures names Eric Linsley managing partner
Mr. Linsley joined Pappas Ventures in early 2000 and has played an instrumental role in raising and deploying each of Pappas' last three funds. Most recently, he and founder Art Pappas led the team that closed on Pappas Ventures IV, a $102 million venture capital fund focused on the life sciences sector. Mr. Linsley has been a venture capital investor for 18 years. From 1991 to 1997, he worked as an investment professional with Ampersand Ventures, a leading venture capital firm based in Boston.
As a partner at Ampersand, he held interim management positions in operating and financial roles for various industrial products and health care companies. Immediately prior to joining Pappas, Mr. Linsley served as Chief Financial Officer of TriPath Imaging, Inc., a medical device company that was acquired in 2006 by Becton Dickinson. He played a key role in the three-way merger between AutoCyte, NeoPath and Neuromedical Systems that created TriPath.
Prior to the formation of TriPath, Mr. Linsley served as Chief Financial Officer and Vice President of Operations at AutoCyte, where he led the company in a successful public equity offering in 1997. Mr. Linsley previously served as a management consultant with Bain & Co. and McKinsey & Co., and was a certified public accountant with Arthur Andersen LLP. He is currently a director of BaroSense, BioSyntech (TSX: BSY), Cequent Pharmaceuticals and FlowCardia. ■